PBYI 10-Q: SEC filing
Puma Biotechnology
Filed with the SEC on · accession 0001437749-26-035912
PBYI filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Puma Biotechnology filed its Q3 2026 Form 10-Q, reporting quarterly financial results including product revenue, royalty revenue, and operating expenses for the period ended September 30, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for PBYI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PBYI?
Click hereFrequently asked questions
What did PBYI file with the SEC on Nov 9, 2026?
PBYI filed a 10-Q (SEC filing). Puma Biotechnology filed its Q3 2026 Form 10-Q, reporting quarterly financial results including product revenue, royalty revenue, and operating expenses for the period ended September 30, 2026.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other PBYI SEC filings
Get alerts when PBYI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days